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Esther Setién-Suero , Vicent Balanzá-Martı́nez , Gabriel Selva-Vera , Juan Carlos Ruiz-Ruiz ,
Joan Vila-Francés , Anabel Martinez-Aran , Juliana Vivas-Lalinde , Candela Conforte-Molina ,
Constanza San-Martı́n , Carlos Martı́nez-Pérez , Inmaculada Fuentes-Durá ,
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 Patients with bipolar disorder and their unaffected relatives performed significantly worse 
than healthy controls on the Rey-Osterrieth complex figure test. 
 Bipolar disorder patients and their unaffected relatives showed stable deficits in visual 
memory over 5-year. 
 Unaffected relatives showed an intermediate profile between patients and healthy 
controls in Visual Memory. 
 Impaired Visual Memory could be considered a potential neurocognitive endophenotype 
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Background: Scarce research has focused on Visual Memory (VM) deficits as a possible 
neurocognitive endophenotype of bipolar disorder (BD). The main aim of this 
longitudinal, family study with healthy controls was to explore whether VM dysfunction 
represents a neurocognitive endophenotype of BD. 
Methods: Assessment of VM by Rey-Osterrieth Complex Figure Test (ROCF) was carried 
out on a sample of 317 subjects, including 140 patients with BD, 60 unaffected first-
degree relatives (BD-Rel), and 117 genetically-unrelated healthy controls (HC), on three 
occasions over a 5-year period (T1, T2, and T3). BD-Rel group scores were analyzed 
only at T1 and T2. 
Results: Performance of BD patients was significantly worse than the HC group 
(p<0.01). Performance of BD-Rel was also significantly different from HC scores at T1 
(p<0.01) and T2 (p=0.05), and showed an intermediate profile between the BD and HC 
groups. Only among BD patients, there were significant differences according to sex, 
with females performing worse than males (p=0.03). Regarding other variables, 
education represented significant differences only in average scores of BD-Rel group 
(p=0.01). 
Limitations: Important attrition in BD-Rel group over time was detected, which 
precluded analysis at T3. 
Conclusions: BD patients show significant deficits in VM that remain stable over time, 
even after controlling sociodemographic and clinical variables. Unaffected relatives also 
show stable deficits in VM. Accordingly, the deficit in VM could be considered a 
potential endophenotype of BD, which in turn may be useful as a predictor of the 
evolution of the disease. Further studies are needed to confirm these findings. 





















Endophenotypes are observable characteristics that can be robustly and reliably measured and 
are thought to be strongly genetic in origin (Kosger et al., 2015). Some methods have been 
used to identify the endophenotypic profile associated with mental illnesses such as BD, 
including genetic, neuroimaging, physiological, and neurocognitive measures (Castañeda and 
Tirado, 2008; Glahn et al., 2014). Over time, testable criteria were developed to aid in the 
objective identification of endophenotypes, (Gottesman and Gould, 2003): 1) To be associated 
with the illness within a larger population cluster, that is, when patients and healthy controls 
from the same population are compared, significant differences are found between both 
groups. 2) Dysfunctions have to be independent of the patient’s clinical state, not being 
related to the temporal oscillations of the disease, which can be verified using cross-sectional 
studies comparing euthymic and non-euthymic groups, or with follow-up designs. 3) To be 
heritable and co-segregate within families, to check this criterion it is necessary to design 
studies including control groups and groups or relatives. Additionally, an endophenotype 
should be reproducible in subsequent measurements (Vieta, 2014). Regarding the first 
criterion, numerous research articles, reviews, and meta-analysis, have found several 
neurocognitive deficits that can be identified as suitable candidates to be endophenotypes of 
BD: attention, memory in general and executive functions such as cognitive flexibility, working 
memory, verbal fluency or response inhibition (Castañeda and Tirado, 2008; Bora et al., 2009; 
Maekawa, 2013; Bourne et al., 2013: Glahn et al., 2014; Santos et al., 2014; Volkert et al., 
2016). With regard to the second criterion, to assess “clinical state-independence” in BD, 
several longitudinal studies comparing patients and healthy controls detected neurocognitive 
deficits mostly during periods of euthymia (Lim et al., 2013: Samamé et al., 2014; Cardoso et 
al., 2015; Lee et al., 2014; Russo et al., 2014; Georgiades et al., 2016). In relation to the third 
criterion, despite few existing studies with relatives of patients with BD (BD-Rel), growing 
evidence indicates that several cognitive deficits are also present in unaffected relatives of 
patients with BD, (Bora et al, 2009; Arts et al, 2011; Balanzá-Martínez et al, 2008; Miskowiak et 
al, 2017). This suggests that some neurocognitive deficits may be considered endophenotype 
candidates for the disorder (Russo et al., 2014). These studies have shown that the cognitive 
performance of unaffected BD-Rel is between that of patients with BD and that of healthy 














set shifting and planning (Drysdale et al., 2013; Nehra et al., 2014; Volkert et al., 2016; Tatay-
Manteiga et al., 2018). To our knowledge, in the only prospective longitudinal study that 
includes a BD-Rel group, manual motor speed dysfunction may qualify as a neurocognitive 
endophenotype of BD (Correa-Ghisays et al., 2017).  
Concerning to visual memory as a cognitive function, some other studies have shown that both, 
verbal memory and visual memory (VM) are impaired in patients with BD (Ha et al., 2012). 
Although there are other instruments to measure non-verbal memory or visual memory, the 
Rey-Osterrieth Complex Figure Test (ROCF) has proven to be a useful and recognized 
neuropsychological tool to evaluate visual memory (Shin et al., 2006). In these regards, we 
found that there are a few cross-sectional studies that measure VM with ROCF and 
simultaneously include unaffected first-degree BD-Rel identifying deficits in VM in BD patients 
and also in BD-Rel (Frantom et al., 2008; Kulkarni et al., 2010; Maziade et al., 2011; Tatay-
Manteiga et al., 2018). Conversely, those who have not found deficits in visual functions 
among BD-Rel, do not measured VM or used tests other than the ROCF (Doyle et al., 2005; 
Nehra et al., 2014; Kim et al., 2015). 
To our knowledge, our study is the first to include, at the same time, repeated measurements 
of VM over time and the comparison with unaffected first-degree BD-Rel (Miskowiak et al., 
2017). Therefore, we think that the inclusion of the longitudinal and family components in the 
design may further advance our understanding of the endophenotypic nature of VM in BD.  
The objective of the present 5-year, a follow-up study was to explore if VM dysfunction 
represents a neurocognitive endophenotype of BD. We hypothesize that BD patients, 
regardless of clinical status and medication, and their first-degree relatives will have a worse 
performance in VM tasks than healthy controls. These deficits would remain stable over time 
in both groups, pointing to VM dysfunction as a neurocognitive endophenotype of BD.  
 
2. Methods 














This study is part of larger, ongoing research on severe mental disorders carried out by 
the CIBERSAM-G24 / TMAP-UV in Valencia, Spain. In this follow-up study, 
neurocognitive, clinical and functional data of psychiatric patients, their unaffected 
first-degree relatives and genetically-unrelated healthy volunteers are simultaneously 
assessed three times over a 5-year period (Balanzá-Martínez et al., 2005; Tabarés-
Seisdedos et al., 2008; Salazar-Fraile et al., 2009; Selva-Vera et al., 2010; Correa-
Ghisays et al., 2017).  
2.2. Participants 
This study assessed a sample of 317 adult participants, including 140 BD patients, 60 of 
their unaffected first-degree relatives (parents, siblings, and offspring; BD-Rel) and 117 
genetically unrelated healthy volunteers with no personal and family psychiatric history 
or healthy control group (HC). BD and BD-Rel were recruited from Mental Health Units 
(MHU) at several towns in the province of Valencia (Spain) (Foios, Catarroja, Paterna, 
Sagunto and Gandía), the psychiatry outpatient clinic of the University Hospital Dr. 
Peset and the Day-Hospital Miguel Servet, in Valencia City. HC group came from the 
same geographical area of residence, and as far as possible were matched in sex, age 
and years of education. Experienced psychiatrists confirmed a diagnosis of BD patients 
according to the Diagnostic and Statistical Manual of Mental Disorders - DSM most up-
to-date at the time from their inclusion in the study (American Psychiatric Association, 
1996; 2000; 2014), also validating that all were clinically stable and provided the 
pertinent clinical history data. The following exclusion criteria were used for the three 
groups: any substance use disorder in the past six months or be under the influence of 
toxic substances upon evaluation; illiteracy and/or severe intellectual disability; 
suffering from head trauma, motor dysfunctions, neurological disorders, cognitive 
impairment deemed as dementia, established ad-hoc or previously diagnosed 
following current DSM criteria, treatment with electroconvulsive therapy (TEC) or any 
medical condition that might hinder the correct performance of the tests. For the HC 














illness and, only for the HC group, a family history of severe mental disorder. All 
participants signed an informed consent form approved by the Ethics Committee of the 
University Clinical Hospital of Valencia.  
2.3. Assessments 
The assessments took place at three moments: The second time point (T2) took place 
1-2 years after the first assessment (baseline or T1), whereas the third time point (T3), 
took place an average not less than five years after T1. Due to significant attrition in the 
BD-Rel group over time, their performance could be assessed only at T1 and T2. 
2.3.1. Sociodemographic and clinical variables 
Sociodemographic data were collected at each assessment (T1, T2, and T3): sex, age, 
educational years, living status and occupational status. For patients, several clinical 
data were collected: age of onset, family history of severe mental illness, 
psychopharmacological treatment (comparison of “on and off” patients, but doses 
were not taken into account) and adherence to treatment. In order to register BD 
patients mood state over the study period, “euthymia” variable was included, which 
was obtained from scores on the Young Mania Rating Scale (YMRS) (Young et al., 1978; 
Colom et al., 2002) and the Hamilton Rating Scale for Depression (HRSD-17) (Hamilton, 
1960; Ramos-Brieva and Cordero-Villafáfila, 1986). Scores were registered as “1” if 
psychometric criteria for euthymia were fulfilled (defined as a total YMRS score, less or 
equal than 6 and a total HRSD-17 scoreless or equal than 8) and “0” if a non-euthymic 
state was found (defined as higher scores in one or both scales). 
2.3.2. Visual memory assessment 
The Rey-Osterrieth Complex Figure Test (ROCF) Figure A (Rey, 1999) was used to 
measure VM as part of an extensive battery of tests used in the major original research 
mentioned above. Participants copied the figure and then were asked to draw the 














(fRey20). The direct score at each moment represents the number of elements in the 
figure that the subject can remember and reproduce correctly of a total of 18 units. 
Each element is scored from 0 to 2, with 36 points being the maximum score. The 
initial copy of the figure is also scored, and participants with scores one standard 
deviation (3.45) below the mean (30.48) were excluded according to the original 
scoring parameters. Applied to 21 subjects (19 BD, 1 BD-Rel and 1 HC). 
2.4. Statistical analysis 
For the statistical analysis, we compared BD and BD-Rel groups direct scores with HC 
group scores. As the two VM variables (fRey2 and fRey20) were highly correlated 
(R=0.94), we decided to use an overall score of ROCF test (fReyT), calculated as the 
mean of the scores in the two subtests, which represents the cognitive domain “Visual 
Memory”. 
VM showed a high inverse Pearson correlation with age (R=-0.45; p<0.001), so the 
effect of age was controlled at three-time points, by adjusting the linear trend of the 
fReyT scores to zero using the least squares regression adjustment, taking HC scores at 
T1 as a reference. This adjustment corrects the time and learning effect 
simultaneously. Fig. 1 shows the fReyT scores of all study participants and the linear 
trend with age, indicating that VM performance decreases more with age in the BD 
group than in BD-Rel and HC (p<0.001). 
We analyzed the variability of the fReyT values in each group by using a pairwise t-test. 
P-values were adjusted using Bonferroni correction (p<0.007).  
We performed an ANCOVA of the fReyT at each-time point. The covariates included all 
the variables listed in Table 1 except the family relationship (only valid for BD-Rel), 
group and age, which was already controlled by the linear adjustment.  
















A summary of the sociodemographic and clinical characteristics of the participants can 
be found in Table 1. At T1, BD patients represented 44%, BD-Rel 19% and HC 37% of 
the total sample. Females accounted for 62% of the total sample. The mean age of the 
whole sample was 41 years, and the mean number of years of education was 12.3. 
According to YMRS and HRSD-17 scales, 80.7% of patients with BD were euthymic at 
T1. At T2, 193 participants were assessed: 93 BD, 10 BD-Rel and 90 HC; and at T3, 90 
participants remained in the study: 65 BD and 25 HC. BD-Rel were excluded at this 
study time. 
fReyT mean scores for all groups at T1 and T2, and only for BD and HC groups at T3, are 
shown in Table 2. Overall, HC outperformed both BD and BD-Rel, and BD-Rel 
performed better than BD patients (Fig. 2). 
Differences between BD patients an HC in fReyT were significant over the three 
assessments (p<0.001). Differences between patients and BD-Rel in fReyT were 
significant only at T1 (p=0.002), and not significant at T2 (p=0.60). These differences 
remained unchanged when non-euthymic BD patients (n=31) were excluded from 
analysis. Differences between BD-Rel and HC in fReyT were significant at T1 p<0.001 
and T2 approached the statistical significance (p=0.05) (Table 3). 
The analysis of the relationship between sociodemographic and clinical variables and 
fReyT at T1 (Table 4) showed significant differences only in the patients’ group 
according to sex (p=0.03), with worse performance among women. In the BD-Rel 
group, only years of education had a significant effect on VM performance (p=0.01). At 
T2, BD-Rel group showed significant differences according to sex (p=0.03), BD and HC 















A repeated-measures analysis was performed, but the result showed no significant 
differences on the VM evolution between groups, because the differences between 
subjects are more significant than the differences between periods for each individual. 
 
4. Discussion 
To the best of our knowledge, this is the first longitudinal study including three groups 
(patients with BD, BD-Rel, and HC), aimed to examine whether VM dysfunction may be 
considered an endophenotype of BD. 
According to some of the criteria commonly used to determine neurocognitive 
endophenotypes (Gottesman and Gould, 2003; Hasler et al., 2006), our findings 
support that impaired VM, assessed with the ROCF test, meets the criteria to be 
considered as a useful endophenotype of genetic vulnerability in BD patients for 
several reasons: 
First, VM is associated with the disease within a population. We found significant 
differences in the performance of patients about the performance of HC after 
controlling sociodemographic variables. Concerning the presence of deficit associated 
upon diagnosis, patients with BD had several deficits, specifically on visual memory, 
working memory, attention, processing speed (Romero et al., 2016). Furthermore, 
another longitudinal study (Santos et al., 2014) concluded that patients with BD 
performed worse than control subjects in all assessed cognitive domains, including 
visual memory. Regarding this criteria, in a naturalistic longitudinal study (six weeks of 
treatment) compared patients with BD type I and II, and unipolar depression, in 
depressed mood, there is not difference between groups in the majority of functions 
evaluated. However, the patients with bipolar disorder II and patients with unipolar 














impairment is more characteristic of the bipolar disorders I and II than of the unipolar 
depression (Xu et al. 2012). 
Second, in the present study, the clinical state independence supported by the 
longitudinal approach showed that BD patients’ deficits were consistently stable at 
three measurements over 5 years, regardless of their clinical state. Moreover, these 
deficits remained after excluding non-euthymic patients from the analysis. 
Furthermore, Langenecker et al. (2010) compared HC with three bipolar patients’ 
groups: euthymic, depressed and hypomanic/mixed. Controls outperformed euthymic 
and depressed patients on visual memory, among other cognitive functions. In the 
abovementioned study (Xu et al., 2012), depressed patients with either bipolar 
disorders type I and II or unipolar depression showed several cognitive dysfunctions, 
including visual memory. However, during clinical remission, cognitive performance 
improved, except for deficits in processing speed and visual memory, which represents 
a potential trait deficit in those domains. In a 6-month, double-blind trial with patients 
with bipolar depression, Toniolo et al. (2017) found that visual memory deficits 
remained stable over time. Other studies have also found that deficits in VM are 
independent of medication (Wilder-Willis et al., 2001; Lohr and Caligiuri, 2006), which 
concurs with present findings. 
Third, our results support that VM dysfunction is heritable and co-segregates within 
families as there were significant differences between BD-Rel and HC performance and 
these deficits remained stable over time. Moreover, although relatives outperformed 
patients at T1, these significant differences disappear at T2. Additionally, an 
intermediate pattern of performance in relatives was observed. In this regard, other 
studies have found VM deficits among BD-Rel (Frantom et al., 2008; Maziade et al., 
2009; Kulkarni et al., 2010; Tatay-Manteiga et al., 2018). Conversely, other studies did 
not find significant differences between BD-Rel and HC although relatives’ performance 
fell between that of controls and patients (Doyle et al., 2009; Nehra et al., 2014; Kim et 














Organization) or assessed with tests other than the ROCF, such as the Korean complex 
figure test (Kim et al., 2015) or Brief Visuospatial Memory Test-Revised (Nehra et al., 
2014). 
If confirmed, these results suggest that impaired VM represents an endophenotype of 
BD and thus should be the addressed by cognitive-enhancement and functional 
remediation efforts (Fuentes-Durá et al., 2012; Bonnin et al., 2016; Miskowiak et al., 
2016; Van Rheenen et al., 2018). 
The clinical relevance of the present research is to present VM dysfunction as a new BD 
neurocognitive endophenotype, that may be useful as a predictor of clinical evolution 
or to guide preventive or rehabilitative strategies. 
 
Limitations 
The analysis and comparisons of repeated measures should be viewed with caution, 
since substantial sample size attrition took place over the 5-year follow-up period, then 
weakening the reliability of longitudinal results, especially for relatives. 
The VM functioning was evaluated with a single test: ROCF, which could hinder 
comparisons with other studies with different tests. 
The relationship between neurocognitive performance and polypharmacy, 
comorbidities, social functioning and quality of life (Balanzá-Martínez et al., 2015; Dias 
et al., 2012; Sánchez-Moreno et al., 2018; Tatay-Manteiga et al., 2019) were not 
examined. 
Although these factors are not considered as criteria for the identification of 













education and VM performance of three groups over time has to be analyzed in studies 
with larger samples. 
5. Conclusion
Significant differences in VM BD and BD-Rel performance compared with HC remain 
stable over time, even after sociodemographic variables confounder's adjustment (age, 
sex only for BD group, and years of education only for BD-Rel group). 
Clinical variables, clinical status and pharmacological treatment do not seem to 
influence negatively on patients’ performance on VM. 
Therefore, the deficit in VM could be considered a potential endophenotype of BD. 
However, to thoroughly explain VM dysfunction as an endophenotype of BD patients, it 
will require a further examination including others factors, larger samples, longer 
terms, more repeated measurements, and ideally with randomized clinical trials that 
consider cognition such as a primary outcome (Martinez-Arán and Vieta, 2015). 
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Table 1: Sociodemographic and clinical characteristics of the sample by groups at basal time of the study 
Characteristics  
BD BD-Rel HC Total 
n % n % n % n % 
140 44 60 19 117 37 317 100 
Family relationship 
Parents   6 10     
Siblings    45 75     
Children   9 15     
Sex 
Male 57 41 20 33 46 39 123 38 
Female 83 59 40 67 71 61 194 62 
Age 
Min. 18  18  18  18  
Mean 43  43  36  41  
Max. 65  78  63  78  
Years of education 
Min. 0  0  8  0  
Mean 11  12  14  12,3  
Max. 27  24  22  27  














Yes 90 64 50 83 87 74 227 74 
Occupational status 
No 102 73 16 27 18 15 136 38 
Yes 38 27 44 73 99 85 181 62 
Young Mania Rating Scale (YMRS) 
Min. 0  0  0  0  
Mean 2  0  0  0  
Max. 18  7  5  18  
Hamilton Rating Scale for Depression (HRSD-17) 
Min. 0  0  0  0  
Mean 4  1  1  2  
Max. 21  23  10  23  
Euthymic state 
No 27 19       
Yes 113 81       
Antipsychotics 
No 58 48       
Yes 62 52       
Antidepressants 
No 85 71       
Yes 35 29       
Lithium 
No 51 43       
Yes 68 57       
Carbamazepine 
No 99 84       
Yes 19 16       
Benzodiazepines 
No 53 45       
Yes 66 55       
Abbreviations: BD: Patient with Bipolar Disorder. BD-Rel: Relative. HC: Healthy Control. n: group size. %: percentage. 
 
Table 2: Overall score of Rey-Osterrieth Complex Figure Test (ROCF) means 
by groups at three time points 

















24.9(6.3) 28.0(6.3) 31.5(5.8) 27.2(6.7) 29.2(9.3) 34.2(5.5) 27.1(6.6) 34.6(4.8) 
Mean (Standard deviation). Abbreviations: T1, T2 and T3: Three times of the study. BD: Patient with Bipolar Disorder. 




Table 3: Differences by groups at three time points 
 T1 T2 T3 
Groups T p T p t p 
BD < HC  -8.62 <0.001 -7.40 <0.001 -5.09 <0.001 
BD < BD-Rel -3.33 0.002 -0.94 0.60   
BD-Rel < HC -3.56 <0.001 -2.33 0.05   
Abbreviations: T1, T2 and T3: Three times of the study. BD: Patients with Bipolar Disorder.  
















Table 4: ANCOVA with independents variables at three time points 
 T1 T2 T3 
 BD BD-Rel HC BD BD-Rel HC BD HC 
Variable F p F p F p F P F p F p F p F p 
Sex 4.52 0.03 1.05 0.30 0.21 0.64 0.09 0.75 9.6 0.03 0.00 0.99 1.76 0.19 0.06 0.79 
Years of education 2.48 0.12 6.35 0.01 1.40 0.23 9.03 <0.01 2.06 0.22 3.75 0.05 3.29 0.08 0.70 0.41 
Status of coexistence 1.03 0.31 0.01 0.90 0.37 0.54 0.00 0.96 -- -- 1.29 0.25 1.81 0.19 1.89 0.18 
Occupational status 0.04 0.83 0.35 0.55 1.06 0.25 0.00 0.98 3.07 0.15 0.06 0.80 0.17 0.68 0.07 0.79 
YMRS 2.08 0.15     2.71 0.12     0.21 0.64   
HRSD-17 0.03 0.85     0.29 0.59     0.00 0.98   
Euthymic state 1.05 0.30     0.14 0.70     0.11 0.73   
Antipsychotics 0.46 0.49     2.10 0.16     0.21 0.64   
Antidepressant 0.21 0.64     0.29 0.59     0.67 0.42   
Lithium 2.78 0.10     0.00 0.82     2.14 0.15   
Carbamazepine 0.44 0.50     2.04 0.17     2.91 0.10   
Benzodiazepines 0.00 0.92     0.68 0.42     0.05 0.81   





















































Figure 1: Linear trend with age. Abbreviations: BD: Patients with Bipolar Disorder. 
BD-Rel: Relative of patient. HC: Healthy control. 
Figure 2: Improvement of the three groups’ fReyT scores at three time points. Abbreviations: BD: 
Patients with Bipolar Disorder. BD-Rel: Relative of patient. HC: Healthy control. 
